Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model
Therapeutics · 2024
DOI: 10.3390/therapeutics1010003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutics, 2024. Verfasst von Arman Romiani und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Foundation.
Abstract (Originalsprache)
Background/Objectives: Neuroblastoma (NB) is a childhood cancer with heterogeneous characteristics, posing challenges to effective treatment. NBs express somatostatin receptors that facilitate the use of somatostatin analogs (SSTAs) as tumor-seeking agents for diagnosis and therapy. High-risk (HR) NBs often have gain-of-function mutations in the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). Despite intensive multimodal treatment, survival rates remain below 40% for children with HR-NB. The aim of this work was to investigate the combined effect of the SSTA 177Lu-octreotide with the ALK inhibitor lorlatinib.
Methods
Mice bearing human HR-NB CLB-BAR tumors were treated with lorlatinib, 177Lu-octreotide, and a combination of these pharmaceuticals or saline (control). Tumor volume was monitored and tumor samples were evaluated for cleaved caspase-3 and expression of 84 human genes involved in apoptosis.
Results
Combination treatment with 177Lu-octreotide and lorlatinib demonstrated synergistic antitumor effects. An increased number of cleaved caspase 3-positive cells was observed in tumors from mice treated with 177Lu-octreotide alone and in combination with lorlatinib. Modulation of Bcl-2 family gene expression was observed only in the presence of both 177Lu-octreotide and lorlatinib, with BID down-regulated and HRK up-regulated on days 2 and 7, respectively.
Conclusions
The data suggest that ALK signaling pathway inhibition may contribute to radiosensitization in radionuclide therapy with 177Lu-octreotide and could improve treatment outcomes in patients with HR-NB.
Förderung
- Swedish Research Council
- Swedish Cancer Society
- Swedish Childhood Cancer Foundation
- ALF-agreement
- Jubilee Clinic Cancer Research Foundation
- Sahlgrenska University Hospital Research Funds
- Wilhelm and Martina Lundgren Research Foundation
- Assar Gabrielsson Cancer Research Foundation
Zitieren
APA
Romiani, A., Pettersson, D., Rassol, N., Simonsson, K., Bakr, H., Lind, D. E., Kovács, A., Spetz, J., Palmer, R. H., Hallberg, B., Helou, K., & Forssell-Aronsson, E. (2024). Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model. Therapeutics. https://doi.org/10.3390/therapeutics1010003
Vancouver
Romiani A, Pettersson D, Rassol N, Simonsson K, Bakr H, Lind DE, et al. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model. Therapeutics. 2024. doi:10.3390/therapeutics1010003
BibTeX
@article{Romiani2024,
author = {Romiani, Arman and Pettersson, Daniella and Rassol, Nishte and Simonsson, Klara and Bakr, Hana and Lind, Dan E. and Kovács, Anikó and Spetz, Johan and Palmer, Ruth H. and Hallberg, Bengt and Helou, Khalil and Forssell-Aronsson, Eva},
title = {Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model},
journal = {Therapeutics},
year = {2024},
doi = {10.3390/therapeutics1010003}
}
EUVIMED